Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease

Frontiers in Synaptic Neuroscience
Lara Ordóñez-Gutiérrez, Francisco Wandosell

Abstract

The accumulation of extracellular amyloid-beta (Aβ), denoted as senile plaques, and intracellular neurofibrillary tangles (formed by hyperphosphorylated Tau protein) in the brain are two major neuropathological hallmarks of Alzheimer's disease (AD). The current and most accepted hypothesis proposes that the oligomerization of Aβ peptides triggers the polymerization and accumulation of amyloid, which leads to the senile plaques. Several strategies have been reported to target Aβ oligomerization/polymerization. Since it is thought that Aβ levels in the brain and peripheral blood maintain equilibrium, it has been hypothesized that enhancing peripheral clearance (by shifting this equilibrium towards the blood) might reduce Aβ levels in the brain, known as the sink effect. This process has been reported to be effective, showing a reduction in Aβ burden in the brain as a consequence of the peripheral reduction of Aβ levels. Nanoparticles (NPs) may have difficulty crossing the blood-brain barrier (BBB), initially due to their size. It is not clear whether particles in the range of 50-100 nm should be able to cross the BBB without being specifically modified for it. Despite the size limitation of crossing the BBB, several NP derivative...Continue Reading

References

Jan 1, 1995·Clinical Anatomy : Official Journal of the American Association of Clinical Anatomists & the British Association of Clinical Anatomists·A AlzheimerF R Murtagh
Apr 15, 1997·Proceedings of the National Academy of Sciences of the United States of America·B SolomonE Hanan-Aharon
Jul 5, 2001·Proceedings of the National Academy of Sciences of the United States of America·R B DeMattosD M Holtzman
Sep 6, 2002·Journal of Alzheimer's Disease : JAD·Dennis J. Selkoe
May 20, 2003·CNS Drugs·Christopher Janus
Dec 14, 2004·The Journal of Biological Chemistry·Fusheng YangGregory M Cole
Mar 23, 2005·Brain Pathology·Thomas Wisniewski, Blas Frangione
Aug 18, 2006·Journal of Alzheimer's Disease : JAD·Dave Morgan
Sep 22, 2006·Journal of Alzheimer's Disease : JAD·Laura ZhangMark Rosenthal
Jan 25, 2007·Nature Reviews. Molecular Cell Biology·Christian Haass, Dennis J Selkoe
Apr 18, 2008·The Journal of Pharmacology and Experimental Therapeutics·Aynun N BegumSally A Frautschy
Aug 9, 2008·Journal of Alzheimer's Disease : JAD·Félix Hernández, Jesús Avila
Oct 28, 2008·Journal of Alzheimer's Disease : JAD·Einar M Sigurdsson
Nov 13, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Barbara BiscaroRoger M Nitsch
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Claudia BalducciGianluigi Forloni
Jul 9, 2010·Lancet Neurology·Francesca MangialascheMiia Kivipelto
Jul 16, 2010·Acta Neuropathologica·Delphine BocheJames A R Nicoll
Dec 7, 2010·Biomaterials·Spyridon MourtasSophia G Antimisiaris
Dec 17, 2010·Journal of Internal Medicine·D Morgan
Mar 5, 2011·Journal of Neuroscience Research·J Gregor SutcliffeBrian S Hilbush
May 27, 2011·Science Translational Medicine·Jasvinder K AtwalRyan J Watts
Dec 27, 2011·Pharmacology & Therapeutics·Haythum O TayebFrank I Tarazi
Mar 6, 2012·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Eleni MarkoutsaSophia G Antimisiaris
Apr 3, 2012·Nanomedicine : Nanotechnology, Biology, and Medicine·Barbara KlajnertEduardo Fernandez-Megia
Jun 21, 2012·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Takaaki MoriTetsuya Suhara
Jul 13, 2012·The New England Journal of Medicine·Randall J BatemanUNKNOWN Dominantly Inherited Alzheimer Network
Oct 23, 2012·Journal of Neurology, Neurosurgery, and Psychiatry·Yasumasa YoshiyamaJohn Q Trojanowski
May 7, 2013·Annual Review of Biomedical Engineering·Gang BaoSheng Tong
Sep 14, 2013·Neuro-degenerative Diseases·Einar M Sigurdsson
Oct 24, 2013·Molecular Neurodegeneration·Cynthia A Lemere
Nov 15, 2013·The Journal of Biological Chemistry·Fredrik OlssonJohan Lundkvist

❮ Previous
Next ❯

Citations

May 22, 2021·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·Isabela F L MotaMárcia R Mortari

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APOE

Apolipoprotein E (APOE) polymorphic alleles are major genetic risk factors for Alzheimer's disease. Discover the latest research on APOE and other genetic determinants of Alzheimer's disease here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

Alzheimer's Disease: Endosomes

Dysfunctional endosomal trafficking may be associated with Alzheimer’s disease (AD) pathology. Targeting the endosome may advance treatment options for AD. Here is the latest research on endosomes and AD.

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.